- Home
- EXEL vs RPRX Comparison
EXEL vs RPRX Comparison
Compare EXEL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- RPRX
- Stock Information
- Founded
- EXEL 1994
- RPRX 1996
- Country
- EXEL United States
- RPRX United States
- Employees
- EXEL N/A
- RPRX N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- RPRX Health Care
- Exchange
- EXEL Nasdaq
- RPRX Nasdaq
- Market Cap
- EXEL 12.0B
- RPRX 13.9B
- IPO Year
- EXEL 2000
- RPRX 2020
- Fundamental
- Price
- EXEL $45.40
- RPRX $36.01
- Analyst Decision
- EXEL Buy
- RPRX Strong Buy
- Analyst Count
- EXEL 18
- RPRX 4
- Target Price
- EXEL $44.29
- RPRX $46.75
- AVG Volume (30 Days)
- EXEL 2.7M
- RPRX 3.0M
- Earning Date
- EXEL 07-28-2025
- RPRX 08-06-2025
- Dividend Yield
- EXEL N/A
- RPRX 2.44%
- EPS Growth
- EXEL 237.58
- RPRX 37.60
- EPS
- EXEL 2.20
- RPRX 2.45
- Revenue
- EXEL $2,298,922,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- EXEL $9.93
- RPRX $29.35
- Revenue Next Year
- EXEL $13.17
- RPRX $7.58
- P/E Ratio
- EXEL $20.60
- RPRX $14.72
- Revenue Growth
- EXEL 24.49
- RPRX 1.13
- 52 Week Low
- EXEL $22.20
- RPRX $24.05
- 52 Week High
- EXEL $49.62
- RPRX $36.89
- Technical
- Relative Strength Index (RSI)
- EXEL 57.52
- RPRX 56.47
- Support Level
- EXEL $43.86
- RPRX $35.24
- Resistance Level
- EXEL $45.52
- RPRX $36.89
- Average True Range (ATR)
- EXEL 1.44
- RPRX 0.59
- MACD
- EXEL -0.07
- RPRX -0.10
- Stochastic Oscillator
- EXEL 39.60
- RPRX 47.31
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.